Free Trial
OTCMKTS:CHGCY

Chugai Pharmaceutical Q4 2024 Earnings Results & Report

Chugai Pharmaceutical logo
$19.96 -0.01 (-0.05%)
As of 03:58 PM Eastern

Chugai Pharmaceutical reported Q4 2024 earnings on January 30, 2025. The company reported EPS of $0.18.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens

Chugai Pharmaceutical EPS Results

Actual EPS
$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chugai Pharmaceutical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Chugai Pharmaceutical's next earnings date is estimated for Friday, October 23, 2026, based on past reporting schedules.

Conference Call Resources

Chugai Pharmaceutical Q4 2024 Earnings FAQ

Chugai Pharmaceutical (OTCMKTS:CHGCY) reported earnings of $0.18 per share for Q4 2024. The report was announced on Thursday, January 30, 2025.

Chugai Pharmaceutical's next earnings date is estimated for Friday, October 23, 2026. MarketBeat tracks confirmed and estimated earnings dates for Chugai Pharmaceutical on the company's earnings history page.

Chugai Pharmaceutical Earnings Headlines

CHGCY - Chugai Pharmaceutical Co., Ltd.
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
Chugai Pharmaceutical Co. Ltd. ADR
See More Chugai Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email.

About Chugai Pharmaceutical

Chugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer. The company also develops antibody-based therapies and other biologic and small-molecule medicines.

Founded in 1925 and headquartered in Tokyo, Chugai operates primarily in Japan while serving international markets through its global business and strategic relationship with Roche. Chugai and Roche have maintained a strategic alliance since 2002, under which Roche distributes certain Chugai-developed products internationally and Chugai markets selected Roche products in Japan. Chugai is listed in Japan, and its American depositary shares trade over the counter under the symbol CHGCY.

View Chugai Pharmaceutical Profile